Researchers at Arizona State University have developed a urine test that identifies autism by examining gut-derived metabolites. This method, which boasts 90 percent accuracy,could replace or supplement traditional behavioral assessments to provide much faster diagnoses for children.

The 1,882% spike in tryptophan-derived metabolites

According to a study published in Molecular Psychiatry, the test focuses on 17 microbial metabolites. These molecules, which are products of gut bacteria, showed significantly elevated levels in the autistic group. The research, which examined 52 autistic and 47 neurotypical children aged two to 11, found that eight tryptophan-derived metabolites were as much as 1,882 percent higher in the autistic group compared to their neurotypical peers.

While neurotypical children showed no elevated metabolites on average, autistic children typically had three. These metabolites are thought to mimic altered versions of serotonin and dopamine, the neurotransmitters responsible for mood, cognition, and memory. The researchers suggest these chemical shifts may underlie common autistic behaviors, such as difficulties with speech and social interaction.

Defining the ASD-MDM subtype through gut health

The research team, led by first author Christina Flynn and corresponding author James Adams, is proposing a new autism subtype labeled ASD-MDM. This subtype is directly linked to microbially-derived metabolites and could potentially account for up to 90 percent of autism cases.

By identifying this biological marker, the researchers suggest that treatments could eventually move toward microbiota-based intervnetions. This might include the use of probiotics or even fecal transplants to lower metabolite levels and alleviate symptoms. Such a shift would move autism care toward more personalized, biology-driven medical protocols.

Moving past the one-in-31 diagnosis bottleneck

As autism diagnoses rise to one in 31 children in the United States, the current diagnostic process is struggling to keep pace. Traditional methods rely heavily on subjective observations, cognitive tests,and lengthy questionnaires, which often result in delays of months or even years.

As reported by the study's authors, a biological test could validate autism as a physiological condition rather than just a behavioral one. This shift has the potential to reduce parental guilt and the stigma often associated with neurodevelopmental disorders, as it provides an objective biological basis for the diagnosis.

The Arizona-centric and gender-skewed data gap

Despite the promising 90 percent accuracy rate, several critical questions remain regarding the study's scope. The researchers noted that the cohort was primarily based in Arizona and consisted mostly of male participants, which limits how broadly the results can be applied to the global population.

It remains unknown if these metabolite levels will present differently in female children or in populations outside of the American Southwest. Furthermore, while the test identifies high-risk children, the medical community must still conduct larger, more diverse studies to confirm if this urine-based screening can be integrated into standard clinical practice.